Amgen

Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.

Leadership read: Consolidation shifts the leadership question from growth to integration. For Amgen in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-08-19 · context →

Amgen experienced a cybersecurity incident with sensitive data stolen

Leadership read: A breach is a governance event before it is a technical one. For Amgen in Biotech & Pharma, the hiring consequence is rarely more engineers; it is senior accountability, security, risk and data governance reporting high enough to change decisions. Across Americas, watch whether the response is a hire or a contractor; that distinction says how the board has read it.

curated · 2026-07-31 · context →

Amgen is advancing MariTide, a monthly weight-loss injection, through 6 Phase 3 trials as a direct competitor to Eli Lilly and Novo Nordisk's weekly GLP-1 drugs. The product is positioned to enter the market with a convenience advantage.

Leadership read: Six simultaneous Phase 3 trials is not a pipeline posture; it is a commercial commitment. Running trials in parallel at that scale is expensive and operationally complex; it signals that Amgen has pre-decided to move fast to regulatory submission regardless of which indication data lands first. The consequence is that MariTide is no longer a research asset being evaluated for commercial viability. It is a launch program with a defined differentiation thesis, dosing interval, already baked into the trial design. That forces Amgen to build, now, the payer and provider access infrastructure that GLP-1 incumbents spent years constructing. The related signals in this batch are drawn broadly from product launches across fintech, defense, and quantum hardware; there is no cluster of comparable biopharma or obesity-drug signals in the 90-day set to anchor a density argument. What is visible in public markets, however, is that the GLP-1 category has attracted challenger entries from Roche, Structure Therapeutics, and Viking Therapeutics over the same period, each with distinct differentiation angles. Amgen's monthly-dosing bet fits that pattern of incumbents being attacked on convenience and adherence vectors rather than efficacy alone. Companies entering late into a category with dominant branded competitors face concentrated demand for commercial and market-access leadership that can negotiate formulary position from a disadvantaged baseline, alongside regulatory operations capable of managing parallel indication submissions without compressing timelines.

curated · 2026-07-29 · context →

European Commission approved Amgen's IMDYLLTRA® for extensive-stage small cell lung cancer treatment, demonstrating 40% reduction in death risk versus chemotherapy in Phase 3 trial

curated · 2026-06-01 · context →